Download our sample post-conference report now or receive the full version by contacting us.
The 2022 ASCO Annual Meeting has concluded and in its wake lies 135 cytokine-related abstracts that have been carefully screened and added to the Beacon database. Of these 135 abstracts, 132 presented clinical trial data, and the remaining 3 presented preclinical data.
The most common cytokine class of drugs with clinical data presented was the colony stimulating factors (40%), followed by interleukins (34%). In trial data, The single most studied disease for cytokine drugs at ASCO this year was skin cancer, which was a disease indication in 24% of trials.
For more insight please download the sample, contact us, or request a demo.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements.